{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:08:56Z","timestamp":1747224536641,"version":"3.40.5"},"reference-count":20,"publisher":"PAGEPress Publications","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Reports"],"abstract":"<jats:p>Scleromyxedema (SMX), the generalized and sclerodermic form of lichen myxedematous (LM), is a chronic mucinosis characterized by cutaneous manifestation and several systemic comorbidities. Treatment options are limited and there are no definitive therapeutic guidelines. We report a case of a 48-year-old man with scleromyxedema, associated with monoclonal gammopathy and arthritis, who has been successfully treated with intravenous immunoglobulins (IVIg), oral corticosteroids, and methotrexate (MTX). IVIg is the most used first-line therapy for SMX based on its efficacy and well-tolerated nature and has been used for a growing number of skin disorders. In our case, combining IVIg with oral prednisone and MTX allowed better control of skin disease and extra-cutaneous manifestations. To the best of our knowledge, this is the first case of a successful treatment for SMX with a combination of therapeutic strategies and a good safety profile.<\/jats:p>","DOI":"10.4081\/dr.2023.9803","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T14:17:51Z","timestamp":1692886671000},"source":"Crossref","is-referenced-by-count":0,"title":["Combination intravenous immunoglobulin, oral prednisone, and methotrexate for managing scleromyxedema: case report and literature discussion"],"prefix":"10.4081","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7255-4120","authenticated-orcid":false,"given":"Gaia","family":"Fasano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-8524","authenticated-orcid":false,"given":"Domenico","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"12448","doi-asserted-by":"crossref","unstructured":"Rongioletti F. Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease. Semin Cutan Med Surg. 2006;25(2):100-104. doi:10.1016\/j.sder.2006.04.001","DOI":"10.1016\/j.sder.2006.04.001"},{"key":"12449","unstructured":"Caudill L, Howell E. Scleromyxedema: a case clinically and histologically responsive to intravenous immunoglobulin. J Clin Aesthet Dermatol. 2014;7(5):45-47."},{"key":"12450","doi-asserted-by":"crossref","unstructured":"Edward M, Fitzgerald L, Thind C, Leman J, Burden AD. Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum. Br J Dermatol. 2007;156(3):473-479. doi:10.1111\/j.1365-2133.2006.07652.x","DOI":"10.1111\/j.1365-2133.2006.07652.x"},{"key":"12451","doi-asserted-by":"crossref","unstructured":"C\u00e1rdenas-Gonzalez RE, Ruelas MEH, Candiani JO. Lichen myxedematosus: a rare group of cutaneous mucinosis. An Bras Dermatol. 2019;94(4):462-469. Published 2019 Oct 17. doi:10.1590\/abd1806-4841.20198478","DOI":"10.1590\/abd1806-4841.20198478"},{"key":"12452","doi-asserted-by":"crossref","unstructured":"Kreuter A, St\u00fccker M, Kolios AG, Altmeyer P, M\u00f6llenhoff K. Skleromyx\u00f6dem. Eine chronisch progressive Systemerkrankung [Scleromyxedema. A chronic progressive systemic disease]. Z Rheumatol. 2012;71(6):504-514. doi:10.1007\/s00393-012-0997-5","DOI":"10.1007\/s00393-012-0997-5"},{"key":"12453","doi-asserted-by":"crossref","unstructured":"Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol. 2013;69(1):66-72. doi:10.1016\/j.jaad.2013.01.007","DOI":"10.1016\/j.jaad.2013.01.007"},{"key":"12454","doi-asserted-by":"crossref","unstructured":"S\u00e1ez-Rodr\u00edguez M, Garc\u00eda-Bust\u00ednduy M, L\u00f3pez-Alba A, et al. Localized lichen myxoedematosus (papular mucinosis) associated with morbid obesity: report of two cases. Br J Dermatol. 2003;148(1):165-168. doi:10.1046\/j.1365-2133.2003.05117.x","DOI":"10.1046\/j.1365-2133.2003.05117.x"},{"key":"12455","doi-asserted-by":"crossref","unstructured":"Rongioletti F, Parodi A, Rebora A. Papular and nodular mucinosis as a sign of lupus erythematosus. Dermatologica. 1990;180(4):221-223. doi:10.1159\/000248034","DOI":"10.1159\/000248034"},{"key":"12456","doi-asserted-by":"crossref","unstructured":"Wong RX, Chia JC, Haber RM. Review of Primary Cutaneous Mucinoses in Nonlupus Connective Tissue Diseases. J Cutan Med Surg. 2018;22(1):65-70. doi:10.1177\/1203475417719053","DOI":"10.1177\/1203475417719053"},{"key":"12457","doi-asserted-by":"crossref","unstructured":"Rongioletti F, Rebora A. Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol. 2001;23(3):257-267. doi:10.1097\/00000372-200106000-00022","DOI":"10.1097\/00000372-200106000-00022"},{"key":"12458","doi-asserted-by":"crossref","unstructured":"Knobler R, Moinzadeh P, Hunzelmann N, et al. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol Venereol. 2017;31(10):1581-1594. doi:10.1111\/jdv.14466","DOI":"10.1111\/jdv.14466"},{"key":"12459","doi-asserted-by":"crossref","unstructured":"Majeski C, Taher M, Grewal P, Dytoc M, Lauzon G. Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema. J Cutan Med Surg. 2005;9(3):99-104. doi:10.1007\/s10227-005-0137-9","DOI":"10.1007\/s10227-005-0137-9"},{"key":"12460","doi-asserted-by":"crossref","unstructured":"Kim S, Park TH, Lee SM, et al. Scleromyxedema with multiple systemic involvement: Successful treatment with intravenous immunoglobulin. Dermatol Ther. 2020;33(3):e13378. doi:10.1111\/dth.13378","DOI":"10.1111\/dth.13378"},{"key":"12461","doi-asserted-by":"crossref","unstructured":"Bidier M, Zschoche C, Gholam P, Enk AH, Hadaschik EN. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes. Acta Derm Venereol. 2012;92(4):408-409. doi:10.2340\/00015555-1299","DOI":"10.2340\/00015555-1299"},{"key":"12462","doi-asserted-by":"crossref","unstructured":"Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291(5503):484-486. doi:10.1126\/science.291.5503.484","DOI":"10.1126\/science.291.5503.484"},{"key":"12463","doi-asserted-by":"crossref","unstructured":"Cokonis Georgakis CD, Falasca G, Georgakis A, Heymann WR. Scleromyxedema. Clin Dermatol. 2006;24(6):493-497. doi:10.1016\/j.clindermatol.2006.07.011","DOI":"10.1016\/j.clindermatol.2006.07.011"},{"key":"12464","doi-asserted-by":"crossref","unstructured":"Binitha MP, Nandakumar G, Thomas D. Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema. Indian J Dermatol Venereol Leprol. 2008;74(3):248-250. doi:10.4103\/0378-6323.41372","DOI":"10.4103\/0378-6323.41372"},{"key":"12465","doi-asserted-by":"crossref","unstructured":"Xu XL, Wu Q, Zeng XS, Sun JF. Combination of betamethasone and methotrexate for the treatment of scleromyxoedema without paraproteinaemia. Eur J Dermatol. 2016;26(4):391-393. doi:10.1684\/ejd.2016.2794","DOI":"10.1684\/ejd.2016.2794"},{"key":"12466","doi-asserted-by":"crossref","unstructured":"Mehta V, Balachandran C, Rao R. Arndt Gottron scleromyxedema: successful response to treatment with steroid minipulse and methotrexate. Indian J Dermatol. 2009;54(2):193-195. doi:10.4103\/0019-5154.53183","DOI":"10.4103\/0019-5154.53183"},{"key":"12467","doi-asserted-by":"crossref","unstructured":"Efthimiou P, Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum. 2008;38(3):188-194. doi:10.1016\/j.semarthrit.2007.10.015","DOI":"10.1016\/j.semarthrit.2007.10.015"}],"container-title":["Dermatology Reports"],"original-title":[],"link":[{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/dr\/article\/download\/9803\/9185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/dr\/article\/download\/9803\/9185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T14:17:57Z","timestamp":1692886677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/dr\/article\/view\/9803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":20,"URL":"https:\/\/doi.org\/10.4081\/dr.2023.9803","relation":{},"ISSN":["2036-7406","2036-7392"],"issn-type":[{"type":"electronic","value":"2036-7406"},{"type":"print","value":"2036-7392"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}